Afstyla
Biological
CSL Behring
Total Payments
$1.8M
Transactions
1,518
Doctors
604
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,526 | 77 | 63 |
| 2023 | $3,652 | 135 | 117 |
| 2022 | $5,481 | 122 | 95 |
| 2021 | $33,723 | 176 | 128 |
| 2020 | $77,714 | 99 | 55 |
| 2019 | $246,276 | 231 | 92 |
| 2018 | $421,999 | 290 | 118 |
| 2017 | $982,542 | 388 | 173 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 142 | 67.4% |
| Honoraria | $381,009 | 131 | 21.5% |
| Travel and Lodging | $106,030 | 132 | 6.0% |
| Food and Beverage | $41,859 | 1,011 | 2.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,748 | 38 | 1.8% |
| Consulting Fee | $15,157 | 6 | 0.9% |
| Education | $1,791 | 58 | 0.1% |
Payments by Type
Research
$1.2M
142 transactions
General
$578,595
1,376 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A | CSL Behring | $1.1M | 0 |
| A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIIISingleChain, CSL627) in Subjects With Severe Hemophilia A | CSL Behring | $51,960 | 0 |
| A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products | CSL Behring | $50,000 | 0 |
| Evaluating the ability of the CDC heat inactivation protocol to inactivate modified hemophilia treatment products | CSL Behring | $7,732 | 0 |
| Phase III Open Label, Multicenter, Extension Study to Assess the Safety & Efficacy of Recombinant CAG Factor VIII in subjest with Severe Hemophilia A | CSL Behring | $3,400 | 0 |
Top Doctors Receiving Payments for Afstyla — Page 6
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology | Crystal River, FL | $89.85 | 4 |
| , MD, PHD | Pediatrics | Toledo, OH | $89.84 | 5 |
| , M.D | Hematology & Oncology | Ocala, FL | $89.20 | 4 |
| , PHYSICIAN ASSISTANT | Physician Assistant | Riverside, CA | $87.42 | 3 |
| , MD | Hematology & Oncology | Newark, NJ | $86.81 | 6 |
| Daniela Egas Bejar | — | Naples, FL | $85.65 | 4 |
| , MD | Family Medicine | El Rito, NM | $84.39 | 1 |
| , ARNP | Family | Daytona Beach, FL | $80.43 | 3 |
| , NP | Nurse Practitioner | San Bernardino, CA | $77.80 | 4 |
| , M.D | Student in an Organized Health Care Education/Training Program | Jersey City, NJ | $77.52 | 1 |
| , M.D., P.H.D | Anatomic Pathology & Clinical Pathology | Baltimore, MD | $77.52 | 1 |
| , MD | Hematology | Hershey, PA | $77.52 | 1 |
| , M.D | Hospitalist | New York, NY | $77.52 | 1 |
| , MD | Anatomic Pathology | New Hyde Park, NY | $77.52 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Atlanta, GA | $77.52 | 1 |
| , MD | Trauma Surgery | Philadelphia, PA | $77.52 | 1 |
| , M.D | Anatomic Pathology & Clinical Pathology | San Juan Capistrano, CA | $77.52 | 1 |
| , MD | Pediatric Hematology-Oncology | Bronx, NY | $77.52 | 1 |
| Sharyl Magnuson Boyle | — | Newport, OR | $77.52 | 1 |
| , MD | Hematology | Saint Louis, MO | $77.52 | 1 |
| , M.D | Hematology | Pittsburgh, PA | $77.52 | 1 |
| , MD, PHD | Blood Banking & Transfusion Medicine | State College, PA | $77.52 | 1 |
| , M.D. M.P.H | Obstetrics & Gynecology | Washington, DC | $77.52 | 1 |
| , MD | Pediatric Hematology-Oncology | Jacksonville, FL | $77.52 | 1 |
| , MD | Pediatric Hematology-Oncology | Cincinnati, OH | $77.52 | 1 |
Ad
Manufacturing Companies
- CSL Behring $1.8M
Product Information
- Type Biological
- Total Payments $1.8M
- Total Doctors 604
- Transactions 1,518
About Afstyla
Afstyla is a biological associated with $1.8M in payments to 604 healthcare providers, recorded across 1,518 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2024. In 2024, $1,526 was paid across 77 transactions to 63 doctors.
The most common payment nature for Afstyla is "Unspecified" ($1.2M, 67.4% of total).
Afstyla is associated with 5 research studies, including "An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A" ($1.1M).